MedTrace Logo

Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications

NCT06573008 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 328

Last updated 2024-12-04

No results posted yet for this study

Summary

This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 and older With Influenza at High Risk of Influenza Complications.

Conditions

  • Influenza, Human

Interventions

DRUG

GP681 40mg

2 x 20mg tablets taken orally

DRUG

GP681 Simulant

Placebo tablets matching GP681 40mg

Sponsors & Collaborators

  • Jiangxi Qingfeng Pharmaceutical Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-11
Primary Completion
2025-12-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06573008 on ClinicalTrials.gov